Fong replaced Brad Lerman as Medtronic’s GC, who retired in 2022 before being lured out of retirement to become CLO at ...

Medtronic is bringing on a medical device industry veteran for its new top lawyer as it prepares for a major organizational ...

It is hard to get excited after looking at Becton Dickinson's (NYSE:BDX) recent performance, when its stock has declined 24% over the past three months. We, however decided to study the company's ...

Intraosseous Infusion Devices revenue is expected to grow by CAGR 6.2% from 2025 to 2032 and reach nearly USD 8.79 Bn. In 2032. From ER to EMS, intraosseous infusion is changing how we deliver urgent ...

To enable awareness and knowledge-sharing around best practices of atherothrombectomy in the treatment of vascular diseases a ...

The "Blood Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The global blood market is poised to expand by USD 2.59 billion from 2024 to 2029, with an anticipated CAGR of 5.7%.

General Surgery Leads, Orthopedic and Cardiovascular Sectors Follow in the OT MarketDublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "Global Operation Theatre Management Market (2025 Edition): Analysis ...

Ivan Fong, 63, was one of the highest-proifile GCs to sign an amicus brief supporting Perkins Coie's legal challenge of ...

Review the current Becton Dickinson & Co (BDX:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if BDX is the best investment for you.